In the present study, we for the first time directly demonstrated that suppression of the MAP kinase and PI3K/Akt pathways enhanced histone acetylation at the NIS promoter as a mechanism for the expression of NIS induced by simultaneously targeting the two pathways and HDAC in human cancer cells. The gene discussed is SLC5A5; the disease is cancer.